iloprost and eicosapentaenoic-acid-ethyl-ester

Coronavirus disease 2019 (COVID 19) was first identified in Wuhan, China near the end of 2019. To date, COVID-19 had spread to almost 235 countries and territories due to its highly infectious nature. Moreover, there is no vaccine or Food and Drug Administration (FDA)-approved drug. More time is needed to establish one of them. Consequently, the drug repurposing approach seems to be the most attractive and quick solution to accommodate this crisis. In this regard, we performed molecular docking-based virtual screening of antiplatelet FDA-approved drugs on the key two viral target proteins: main protease (M

Topics: Cilostazol; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Eicosapentaenoic Acid; Epoprostenol; Humans; Iloprost; Molecular Docking Simulation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; SARS-CoV-2; Spike Glycoprotein, Coronavirus; United States; United States Food and Drug Administration